<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review - Narayan, V - 2018 | Cochrane Library</title> <meta content="Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review - Narayan, V - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012838.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review - Narayan, V - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012838.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012838.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review" name="citation_title"/> <meta content="Vikram Narayan" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Andreas Kahlmeyer" name="citation_author"/> <meta content="University Hospital Erlangen" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="University Hospital of Cologne" name="citation_author_institution"/> <meta content="Michael C Risk" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Connie Bongiorno" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Neil Patel" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Eu Chang Hwang" name="citation_author"/> <meta content="Chonnam National University Medical School, Chonnam National University Hwasun Hospital" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Gerald Gartlehner" name="citation_author"/> <meta content="Danube University Krems" name="citation_author_institution"/> <meta content="Frank Kunath" name="citation_author"/> <meta content="frank.kunath@uk-erlangen.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012838.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/07/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012838.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012838.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012838.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [adverse effects, *therapeutic use]; Antineoplastic Agents, Immunological [adverse effects, *therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Carcinoma [*drug therapy, pathology]; Disease Progression; Docetaxel; Paclitaxel [administration &amp; dosage]; Quality of Life; Taxoids [administration &amp; dosage]; Urinary Bladder Neoplasms [*drug therapy, pathology]; Vinblastine [administration &amp; dosage, analogs &amp; derivatives]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012838.pub2&amp;doi=10.1002/14651858.CD012838.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="uQyIsxpV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012838\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012838\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ms","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012838.pub2",title:"Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum\\u2010containing chemotherapy. A Cochrane Rapid Review",firstPublishedDate:"Jul 23, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012838.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012838.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012838.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012838.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012838.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012838.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012838.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012838.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012838.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012838.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3692 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012838.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/appendices#CD012838-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/table_n/CD012838StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/table_n/CD012838StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0002">Vikram Narayan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0003">Andreas Kahlmeyer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0004">Philipp Dahm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0005">Nicole Skoetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0006">Michael C Risk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0007">Connie Bongiorno</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0008">Neil Patel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0009">Eu Chang Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0010">Jae Hung Jung</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0011">Gerald Gartlehner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information#CD012838-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Frank Kunath</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information/en#CD012838-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 July 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012838.pub2">https://doi.org/10.1002/14651858.CD012838.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012838-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012838-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012838-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012838-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012838-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012838-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012838-abs-0001" lang="en"> <section id="CD012838-sec-0001"> <h3 class="title" id="CD012838-sec-0001">Background</h3> <p>The use of systemic immunotherapy targets is emerging as an important treatment option for metastatic urothelial carcinoma, particularly for patients who cannot tolerate or who fail cisplatin‐based chemotherapy. One such target is the inhibition of the checkpoint protein programmed cell death‐1 (PD‐1) receptor and its ligand (PD‐L1) by monoclonal antibodies. </p> </section> <section id="CD012838-sec-0002"> <h3 class="title" id="CD012838-sec-0002">Objectives</h3> <p>To assess the effects of pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. </p> </section> <section id="CD012838-sec-0003"> <h3 class="title" id="CD012838-sec-0003">Search methods</h3> <p>We performed a Cochrane Rapid Review, limiting our search to published studies in the English language. We searched databases of the medical literature, including the Cochrane Central Register of Controlled Trials and MEDLINE, as well as trial registries including ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). Our search extended from January 2000 to June 2018. </p> </section> <section id="CD012838-sec-0004"> <h3 class="title" id="CD012838-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials except cross‐over trials and cluster randomised trials. We excluded all other study designs. Participants included had locally advanced or metastatic urothelial carcinoma of the bladder, with disease progression during or following platinum‐containing chemotherapy (synonymous with second‐/third‐/fourth‐line therapy). This review focused on pembrolizumab (synonyms: MK‐3475, lambrolizumab, Keytruda). </p> </section> <section id="CD012838-sec-0005"> <h3 class="title" id="CD012838-sec-0005">Data collection and analysis</h3> <p>Two review authors independently classified and abstracted data from the included study. The certainty of evidence was rated according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD012838-sec-0006"> <h3 class="title" id="CD012838-sec-0006">Main results</h3> <p>We identified one randomised controlled trial that included 542 participants, which compared the use of pembrolizumab monotherapy versus chemotherapy for the treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. Results were reported after a median follow‐up of 14.1 months (range 9.9 to 22.1 months). </p> <p><b>Primary outcomes</b> </p> <p>Pembrolizumab probably reduces the risk of death from any cause (hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.59 to 0.90; moderate certainty evidence). This corresponds to 115 fewer deaths (191 fewer to 38 fewer) per 1000 participants with pembrolizumab at 12 months. We downgraded the certainty of evidence one level for imprecision. </p> <p>Pembrolizumab may slightly improve quality of life (change from baseline to week 15 assessed with the Core Quality of Life Questionnaire; higher value reflects better quality of life; scale 0 to 100) with a mean difference (MD) of 9.05, 95% CI 4.61 to 13.50; low certainty evidence). We downgraded the certainty of evidence two levels for study limitations and imprecision. </p> <p><b>Secondary outcomes</b> </p> <p>Pembrolizumab may have little or no effect on disease progression (HR 0.98, 95% CI 0.81 to 1.19; low certainty evidence). This corresponds to three fewer patients (42 fewer to 24 more) whose disease progressed per 1000 participants at 12 months. We downgraded the certainty of evidence two levels for study limitations and imprecision. </p> <p>Pembrolizumab probably improves treatment response (based on complete or partial radiologic response) with a risk ratio (RR) of 1.85, 95% CI 1.24 to 2.77; moderate certainty evidence). This corresponds to 97 more respondents (27 more to 202 more) per 1000 participants with pembrolizumab. We downgraded the certainty of evidence one level for imprecision. </p> <p>Pembrolizumab may have little or no effect on treatment‐related mortality (RR 0.96, 95% CI 0.24 to 3.79; low certainty evidence). This corresponds to one fewer (12 fewer to 44 more) treatment‐related deaths per 1000 participants with pembrolizumab. We downgraded the certainty of evidence two levels for study limitations and imprecision. </p> <p>Pembrolizumab may have little or no effect on discontinuations due to adverse events (RR 0.66, 95% CI 0.39 to 1.10). This corresponds to 54 fewer discontinuations per 1000 participants (95% CI 79 fewer to 7 more). We downgraded the certainty of evidence for study limitations and imprecision. </p> <p>Pembrolizumab may reduce serious adverse events (RR 0.83, 95 CI 0.72 to 0.97; low certainty evidence). This corresponds to 107 fewer serious averse events per 1000 participants (95% CI 19 fewer to 176 fewer). We downgraded two levels for study limitations and imprecision. </p> </section> <section id="CD012838-sec-0007"> <h3 class="title" id="CD012838-sec-0007">Authors' conclusions</h3> <p>The use of pembrolizumab in men with advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy probably improves overall survival when compared with chemotherapy alone. At 12 months follow‐up about 70% of those in the chemotherapy group had died, compared with 59% of those treated with pembrolizumab. We are very uncertain about the effects of pembolizumab on quality of life. Pembolizumab may also improve treatment response rates, and reduce the risk of serious adverse events, but may make little or no difference to discontinuations of treatment due to adverse events. These conclusions are based on a single trial that was sponsored by the producer of pembrolizumab. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012838-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012838-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012838-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012838-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012838-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012838-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012838-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012838-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012838-abs-0005" lang="en"> <h3>Pembrolizumab versus chemotherapy for treating advanced bladder cancer after recurrence/progression following platinum‐based chemotherapy </h3> <p><b>Review question</b> </p> <p>How does pembrolizumab (a newer medicine that works through the body's immune system) compare to chemotherapy in patients with cancer of the inner lining of the urinary system, called urothelial cancer, that has either come back or worsened after treatment? </p> <p><b>Background</b> </p> <p>Medications that target the body's immune system have been used for a long time to treat urothelial cancer. When the cancer has spread to other organs outside the urinary tract, patients are often treated with chemotherapy using medicines called cisplatin or carboplatin (platinum‐containing chemotherapy). However, often the cancer comes back or becomes worse despite treatment. This review considers the evidence for pembrolizumab, which is a member of a new class of medications that work through the immune sytem, and compares it to chemotherapy. </p> <p><b>Study characteristics</b> </p> <p>We considered only randomised controlled trials in this Cochrane Rapid Review, as they offer the most reliable results. This review is current to 20 June 2018. </p> <p><b>Key results</b> </p> <p>We found only one randomised study for our question. Participants included in this trial had metastatic (cancer that has spread to other parts of the body) or advanced cancer that could not be removed by surgery, that had come back or worsened with other chemotherapy. </p> <p>We found that pembrolizumab probably improves overall survival a little (evidence of moderate certainty). It may improve quality of life slightly (low certainty evidence). </p> <p>Pembrolizumab may have little or not effect on the time for the cancer to worsen or advance (low certainty evidence). It probably improves treatment response as seen on X‐ray scans such as computer tomography (moderate certainty of evidence). </p> <p>Pembrolizumab may have little or no effect on deaths resulting from the treatment itself (low certainty evidence) but may result in fewer patients stopping treatment due to unwanted side effects (low certainty evidence). It may also cause less serious side effects. </p> <p>These conclusions are based on a single trial paid for by the company that makes pembrolizumab.</p> <p><b>Certainty of evidence</b> </p> <p>The certainty of evidence ranged from moderate to very low.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012838-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012838-sec-0105"></div> <h3 class="title" id="CD012838-sec-0106">Implications for practice</h3> <section id="CD012838-sec-0106"> <p>Pembrolizumab monotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy compared to chemotherapy probably improves overall survival to a small degree and may also improve quality of life although we are uncertain about this. It may also offer benefits in terms of response rate and rates of serious adverse events. In the setting of limited therapeutic alternatives, there appears to be a role for this agent in the therapeutic armamentarium. </p> </section> <h3 class="title" id="CD012838-sec-0107">Implications for research</h3> <section id="CD012838-sec-0107"> <p>This review identified only one randomised controlled trial to contribute to its findings, and conclusions are limited primarily by imprecision and performance or detection biases. More rigorous trials are necessary in the future. In particular, future studies should place greater emphasis on quality of life assessment. </p> <p>Only a subset of participants appear to benefit from pembrolizumab treatment. There is an urgent need for research to identify such patients prospectively in the future. </p> <p>Furthermore, phase IV post‐marketing studies should be conducted for the evaluation of long‐term drug safety and assessment of rare yet potentially serious adverse events. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012838-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012838-sec-0029"></div> <div class="table" id="CD012838-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> people with advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy </p> <p><b>Setting:</b> multicentre; 120 sites in 29 countries </p> <p><b>Intervention:</b> pembrolizumab </p> <p><b>Control:</b> chemotherapy (vinflunine or docetaxel or paclitaxel) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with chemotherapy</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with pembrolizumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to death from any cause</b> (here: overall mortality at 12‐month follow‐up) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>542<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.73<br/> (0.59 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>695 per 1000 <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 fewer per 1000<br/> (191 fewer to 38 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (Change from baseline to week 15)<br/> Assessed with: EORTC QLQ‐C30<br/> Scale from 0 to 100 (a higher score represents better quality of life)<br/> Follow‐up: from baseline to week 15 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.05 (4.61 to 13.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life (change from baseline to week 15) was ‐8.3 score change <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.05 score change higher<br/> (4.61 higher to 13.50 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Response rate</b> (partial and complete response) </p> <p>Follow‐up: median 14.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>542<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.85<br/> (1.24 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 more per 1000<br/> (27 more to 202 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment‐related mortality</b><br/> Follow‐up: median 14.1 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.24 to 3.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 less per 1000<br/> (12 fewer to 44 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Discontinuation due to adverse event</b><br/> Follow‐up: median 14.1 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.39 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 fewer per 1000<br/> (67 fewer to 11 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Serious adverse events (irrespective of attribution to treatment)</b> </p> <p>Follow‐up: median 14.1 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83</p> <p>(0.72 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 fewer per 1000<br/> (176 fewer to 19 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>RR 0.66, 95% CI 0.39 to 1.10<br/> <br/> <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>RCT</b> : randomised controlled trial; <b>EORTC QLQ‐C30:</b>.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐C30 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for imprecision due to wide confidence intervals. </p> <p><sup>2</sup> Downgraded for study limitations (performance and detection bias) </p> <p><sup>3</sup> Additonal concerns about selective reporting bias but not downgraded further. </p> <p><sup>4</sup> Downgraded for imprecision; 95% CI crosses minimal clinically important difference of 10. </p> <p><sup>a</sup> The baseline risk for death of any cause in the chemotherapy group was assumed to be 69.3% at 12 months as reported by Bellmunt 2017 (at 12 months, the estimated overall survival rate was 43.9% (95% CI 37.8 to 49.9) for participants treated with pembrolizumab and 30.7% (95% CI 25.9 to 36.7) for participants treated with chemotherapy). </p> <p>b Baseline risk for the chemotherapy group at 15 weeks as reported by Bellmunt 2017 ("From baseline to week 15, scores were stable for pembrolizumab (n = 266) (least squares [LS] mean +0.75 [95% CI –2.34 to +3.83]) but worsened for chemotherapy (n = 254) (LS mean –8.30 [95% CI –11.76 to –4.83]); the difference in LS means between arms was 9.05 (95% CI 4.61‐13.48; nominal 2‐sided P &lt; 0.001)"). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012838-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012838-sec-0030"></div> <section id="CD012838-sec-0031"> <h3 class="title" id="CD012838-sec-0031">Description of the condition</h3> <p>According to 2012 GLOBOCAN data (<a href="./references#CD012838-bbs2-0015" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer2013;Available from: http://globocan.iarc.fr:accessed 10/2017. ">GLOBOCAN 2012</a>), urothelial carcinoma of the bladder is the ninth most common malignancy worldwide, with nearly 429,000 new cases and 165,000 cancer‐related deaths every year. In addition to the bladder, urothelial carcinoma can affect the renal pelvis, ureters, and the urethra. A diagnosis is typically established by visualisation of the tumour using cross‐sectional imaging or cystoscopy, or both, followed by transurethral resection, which is both diagnostic and therapeutic. Urothelial carcinoma of the bladder is a heterogeneous entity and can vary in presentation from non‐invasive, low‐grade disease to invasive, high‐grade forms that can rapidly progress to early metastasis and death despite aggressive treatment. Invasive urothelial carcinoma of the bladder is usually treated with radical cystectomy and urinary diversion or with radiotherapy and concomitant chemotherapy (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>; <a href="./references#CD012838-bbs2-0029" title="Leitlinienprogramm Onkologie, DeutscheKrebsgesellschaft , DeutscheKrebshilfe , AWMF . S3 ‐ Guideline for early detection, diagnosis, therapy and aftercare for bladder cancer [S3 ‐ Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms]. leitlinienprogramm‐onkologie.de/Harnblasenkarzinom.92.0.html (accessed 1 October 2017). ">Leitlinienprogramm Onkologie</a>; <a href="./references#CD012838-bbs2-0034" title="SpiessPE , AgarwalN , BangsR , BoorjianSA , BuyyounouskiMK , ClarkPE , et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network2017;15(10):1240‐67. ">NCCN Guideline 2017</a>). The surgical therapy can be combined with neoadjuvant or adjuvant chemotherapy (<a href="./references#CD012838-bbs2-0029" title="Leitlinienprogramm Onkologie, DeutscheKrebsgesellschaft , DeutscheKrebshilfe , AWMF . S3 ‐ Guideline for early detection, diagnosis, therapy and aftercare for bladder cancer [S3 ‐ Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms]. leitlinienprogramm‐onkologie.de/Harnblasenkarzinom.92.0.html (accessed 1 October 2017). ">Leitlinienprogramm Onkologie</a>; <a href="./references#CD012838-bbs2-0034" title="SpiessPE , AgarwalN , BangsR , BoorjianSA , BuyyounouskiMK , ClarkPE , et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network2017;15(10):1240‐67. ">NCCN Guideline 2017</a>). Metastatic urothelial carcinoma is usually treated with palliative chemotherapy (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>; <a href="./references#CD012838-bbs2-0029" title="Leitlinienprogramm Onkologie, DeutscheKrebsgesellschaft , DeutscheKrebshilfe , AWMF . S3 ‐ Guideline for early detection, diagnosis, therapy and aftercare for bladder cancer [S3 ‐ Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms]. leitlinienprogramm‐onkologie.de/Harnblasenkarzinom.92.0.html (accessed 1 October 2017). ">Leitlinienprogramm Onkologie</a>; <a href="./references#CD012838-bbs2-0034" title="SpiessPE , AgarwalN , BangsR , BoorjianSA , BuyyounouskiMK , ClarkPE , et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network2017;15(10):1240‐67. ">NCCN Guideline 2017</a>). The most effective chemotherapy regimens are combination platinum‐based therapies, such as MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin; <a href="./references#CD012838-bbs2-0032" title="LogothetisCJ , DexeusFH , FinnL , SellaA , AmatoRJ , AyalaAG , et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. Journal of Clinical Oncology1990;8(6):1050‐5. ">Logothetis 1990</a>), or a combination of gemcitabine plus cisplatin or carboplatin (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>; <a href="./references#CD012838-bbs2-0029" title="Leitlinienprogramm Onkologie, DeutscheKrebsgesellschaft , DeutscheKrebshilfe , AWMF . S3 ‐ Guideline for early detection, diagnosis, therapy and aftercare for bladder cancer [S3 ‐ Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms]. leitlinienprogramm‐onkologie.de/Harnblasenkarzinom.92.0.html (accessed 1 October 2017). ">Leitlinienprogramm Onkologie</a>; <a href="./references#CD012838-bbs2-0034" title="SpiessPE , AgarwalN , BangsR , BoorjianSA , BuyyounouskiMK , ClarkPE , et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network2017;15(10):1240‐67. ">NCCN Guideline 2017</a>; <a href="./references#CD012838-bbs2-0046" title="von derMaaseH , HansenSW , RobertsJT , DogliottiL , OliverT , MooreMJ , et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology2000;18(17):3068‐77. ">von der Maase 2000</a>). Unfortunately, individuals with advanced urothelial carcinoma often have progression or recurrence of urothelial cancer following a first‐line platinum‐containing regimen for metastatic or inoperable locally advanced disease. These individuals are then often managed supportively or with inferior regimens. Vinflunine is often used in Europe as a second‐line chemotherapy regimen and offers a median overall survival of 6.9 months compared to 4.6 months with best supportive care (<a href="./references#CD012838-bbs2-0009" title="BellmuntJ , FougerayR , RosenbergJE , von derMaaseH , SchutzFA , SalhiY , et al. Long‐term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum‐based chemotherapy. Annals of Oncology2013;24(6):1466‐72. ">Bellmunt 2013</a>). The need for novel therapies in this realm is clear. </p> </section> <section id="CD012838-sec-0032"> <h3 class="title" id="CD012838-sec-0032">Description of the intervention</h3> <p>The use of immunotherapy to treat bladder cancer is well established, particularly the use of intravesical Bacillus Calmette‐Guerin for non‐muscle invasive high‐grade disease (<a href="./references#CD012838-bbs2-0033" title="MoralesA , EidingerD , BruceAW . Intracavitary Bacillus Calmette‐Guerin in the treatment of superficial bladder tumors. The Journal of Urology1976;116(2):180‐3. ">Morales 1976</a>). Systemic immunotherapy targets, such as immune checkpoint receptors and their ligands, have been the focus of several recent clinical trials. For example, the inhibition of the checkpoint protein programmed cell death‐1 (PD‐1) receptor and its ligand (PD‐L1) by monoclonal antibodies (mAb) has elicited effective antitumour responses (<a href="./references#CD012838-bbs2-0039" title="RibasA . Releasing the brakes on cancer immunotherapy. New England Journal of Medicine2015;373(16):1490–2. ">Ribas 2015</a>; <a href="./references#CD012838-bbs2-0043" title="SharmaP , AllisonJP . The future of immune checkpoint therapy. Science2015;348(6230):56‐61. ">Sharma 2015</a>). Administered intravenously every two to three weeks, mAbs have shown promising response rates against urothelial carcinoma (<a href="./references#CD012838-bbs2-0001" title="BellmuntJ , SonpavdeG , WitR , ChoueiriTK , Siefker‐RadtkeAO , PlimackER , et al. KEYNOTE‐045: randomized phase 3 trial of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. Journal of Clinical Oncology2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.tps4571] BellmuntJ , deWitR , VaughnDJ , FradetY , LeeJ‐L , FongL , et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. New England Journal of Medicine2017;376(11):1015‐26. [DOI: 10.1056/NEJMoa1613683] DeWitR , BajorinDF , BellmuntJ , FradetY , LeeJ‐L , FongL . Health‐related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE‐045. Journal of Clinical Oncology2017;35(15 Suppl):4530. [DOI: 10.1200/JCO.2017.35.15_suppl.4530] MerckSharp , DohmeCorp . A study of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK‐3475‐045/KEYNOTE‐045). clinicaltrials.gov/ct2/show/NCT02256436 (accessed 1 November 2017). QuinnD , BellmuntJ , WitR , VaughnDJ , FradetY , LeeJL , et al. Keynote‐045: open‐label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. Asia‐Pacific Journal of Clinical Oncology2017; Vol. 13, issue Suppl S1:35. VaughnDJ , BellmuntJ , FradetY , LeeJL , FongL , VogelzangNJ , et al. Health‐Related Quality‐of‐Life Analysis From KEYNOTE‐045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology2018;36(16):1579‐1587. ">Bellmunt 2017</a>; <a href="./references#CD012838-bbs2-0028" title="KimJW , BellmuntJ , PowlesT , LoriotY , VogelzangMJ , ZambranoCC , et al. Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. Journal of Clinical Oncology2015;33(7 Suppl):297. ">Kim 2015</a>; <a href="./references#CD012838-bbs2-0037" title="PlimackER , BellmuntJ , GuptaS , BergerR , ChowLQ , JucoJ . Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE‐012): a non‐randomised, open‐label, phase 1b study. Lancet Oncology2017;18(2):212‐20. ">Plimack 2017</a>; <a href="./references#CD012838-bbs2-0041" title="RosenbergJE , Hoffman‐CensitsJ , PowlesT , van derHeijdenMS , BalarAV , NecchiA , et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‐based chemotherapy: a single‐arm, multicentre, phase 2 trial. The Lancet2016;387(10031):1909‐20. ">Rosenberg 2016</a>; <a href="./references#CD012838-bbs2-0044" title="SharmaP , CallahanMK , BonoP , KimJ , SpiliopoulouP , CalvoE , et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open‐label, two‐stage, multi‐arm, phase 1/2 trial. The Lancet Oncology2016;17(11):1590‐8. ">Sharma 2016</a>). The mAb pembrolizumab targets the PD‐1 receptor, and a randomised controlled trial comparing pembrolizumab with paclitaxel, docetaxel, or vinflunine chemotherapy in individuals in whom urothelial carcinoma had recurred or progressed after platinum‐based chemotherapy has been reported (<a href="./references#CD012838-bbs2-0001" title="BellmuntJ , SonpavdeG , WitR , ChoueiriTK , Siefker‐RadtkeAO , PlimackER , et al. KEYNOTE‐045: randomized phase 3 trial of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. Journal of Clinical Oncology2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.tps4571] BellmuntJ , deWitR , VaughnDJ , FradetY , LeeJ‐L , FongL , et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. New England Journal of Medicine2017;376(11):1015‐26. [DOI: 10.1056/NEJMoa1613683] DeWitR , BajorinDF , BellmuntJ , FradetY , LeeJ‐L , FongL . Health‐related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE‐045. Journal of Clinical Oncology2017;35(15 Suppl):4530. [DOI: 10.1200/JCO.2017.35.15_suppl.4530] MerckSharp , DohmeCorp . A study of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK‐3475‐045/KEYNOTE‐045). clinicaltrials.gov/ct2/show/NCT02256436 (accessed 1 November 2017). QuinnD , BellmuntJ , WitR , VaughnDJ , FradetY , LeeJL , et al. Keynote‐045: open‐label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. Asia‐Pacific Journal of Clinical Oncology2017; Vol. 13, issue Suppl S1:35. VaughnDJ , BellmuntJ , FradetY , LeeJL , FongL , VogelzangNJ , et al. Health‐Related Quality‐of‐Life Analysis From KEYNOTE‐045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology2018;36(16):1579‐1587. ">Bellmunt 2017</a>). Pembrolizumab was associated with longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy (<a href="./references#CD012838-bbs2-0001" title="BellmuntJ , SonpavdeG , WitR , ChoueiriTK , Siefker‐RadtkeAO , PlimackER , et al. KEYNOTE‐045: randomized phase 3 trial of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. Journal of Clinical Oncology2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.tps4571] BellmuntJ , deWitR , VaughnDJ , FradetY , LeeJ‐L , FongL , et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. New England Journal of Medicine2017;376(11):1015‐26. [DOI: 10.1056/NEJMoa1613683] DeWitR , BajorinDF , BellmuntJ , FradetY , LeeJ‐L , FongL . Health‐related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE‐045. Journal of Clinical Oncology2017;35(15 Suppl):4530. [DOI: 10.1200/JCO.2017.35.15_suppl.4530] MerckSharp , DohmeCorp . A study of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK‐3475‐045/KEYNOTE‐045). clinicaltrials.gov/ct2/show/NCT02256436 (accessed 1 November 2017). QuinnD , BellmuntJ , WitR , VaughnDJ , FradetY , LeeJL , et al. Keynote‐045: open‐label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. Asia‐Pacific Journal of Clinical Oncology2017; Vol. 13, issue Suppl S1:35. VaughnDJ , BellmuntJ , FradetY , LeeJL , FongL , VogelzangNJ , et al. Health‐Related Quality‐of‐Life Analysis From KEYNOTE‐045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology2018;36(16):1579‐1587. ">Bellmunt 2017</a>). </p> <section id="CD012838-sec-0033"> <h4 class="title">Adverse effects of the intervention</h4> <p>Grade 3 and 4 treatment‐ and immune‐related adverse events were recently reported in 16% and 5%, respectively, of individuals with post‐platinum‐treated advanced urothelial carcinoma using the mAb atezolizumab (<a href="./references#CD012838-bbs2-0041" title="RosenbergJE , Hoffman‐CensitsJ , PowlesT , van derHeijdenMS , BalarAV , NecchiA , et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‐based chemotherapy: a single‐arm, multicentre, phase 2 trial. The Lancet2016;387(10031):1909‐20. ">Rosenberg 2016</a>). Examples of adverse events included elevated lipase and amylase levels, fatigue, rash, and decreased lymphocyte and neutrophil counts (<a href="./references#CD012838-bbs2-0041" title="RosenbergJE , Hoffman‐CensitsJ , PowlesT , van derHeijdenMS , BalarAV , NecchiA , et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‐based chemotherapy: a single‐arm, multicentre, phase 2 trial. The Lancet2016;387(10031):1909‐20. ">Rosenberg 2016</a>). Similar adverse events and adverse event rates were reported in a phase Ib study of pembrolizumab in metastatic urothelial carcinoma, with 5 of 29 participants reporting grade 3 or 4 adverse events (<a href="./references#CD012838-bbs2-0017" title="GuptaS , O'DonnellP , PlimackER , BergerR , MontgomeryB , HeathK , et al. Mp68‐11 a Phase 1B Study of Pembrolizumab (Pembro; Mk‐3475) for Advanced Urothelial Cancer. The Journal of Urology2015;193(4):e861‐2. ">Gupta 2015</a>). Treatment‐related deaths due to pneumonitis and thrombocytopenia were reported in a phase I/II study with nivolumab in a similar population (<a href="./references#CD012838-bbs2-0044" title="SharmaP , CallahanMK , BonoP , KimJ , SpiliopoulouP , CalvoE , et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open‐label, two‐stage, multi‐arm, phase 1/2 trial. The Lancet Oncology2016;17(11):1590‐8. ">Sharma 2016</a>). </p> </section> </section> <section id="CD012838-sec-0034"> <h3 class="title" id="CD012838-sec-0034">How the intervention might work</h3> <p>Checkpoint proteins such as PD‐1 work to inhibit a host's immune response against a tumour cell by preventing T‐cells from attacking the tumour cells that would otherwise be detected as foreign. Tumour cells, including certain urothelial carcinoma cells, have been shown to express high levels of PD‐1 (<a href="./references#CD012838-bbs2-0014" title="FarajSF , MunariE , GunerG , TaubeJ , AndersR , HicksJ , et al. Assessment of tumoral PD‐L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology2015;85(3):703.e1‐6. ">Faraj 2015</a>), thereby enabling them to evade a host's normal immune response. Checkpoint inhibitors such as mAbs targeting PD‐1 and its ligand, PD‐L1, can therefore block what would otherwise be an inhibitory effect of T‐cells, in turn "reactivating" a host's immune system against tumour cells (<a href="./references#CD012838-bbs2-0035" title="ParkJC , HahnNM . Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies. Urologic Oncology: Seminars and Original Investigations2016;34(12):566‐76. ">Park 2016</a>). </p> </section> <section id="CD012838-sec-0035"> <h3 class="title" id="CD012838-sec-0035">Why it is important to do this review</h3> <p>Given the paucity of treatment options available for individuals with advanced urothelial carcinoma who had progression or recurrence of urothelial cancer following a first‐line platinum‐containing chemotherapy (e.g. cisplatin, carboplatin) for metastatic or inoperable locally advanced disease, the need for novel therapeutic targets is evident. Pembrolizumab has emerged as a novel immunotherapy option, but to date no systematic review of the available data has been carried out that has carefully evaluated the certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to better inform clinical practice. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012838-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012838-sec-0036"></div> <p>To assess the effects of pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012838-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012838-sec-0037"></div> <section id="CD012838-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012838-sec-0039"> <h4 class="title">Types of studies</h4> <p>This review is based on a published protocol (<a href="./references#CD012838-bbs2-0048" title="NarayanV , DahmP , SkoetzN , RiskMC , BonfiornoC , PatelN , et al. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review. Cochrane Database of Systematic Reviews2017, Issue 11. [DOI: 10.1002/14651858.CD012838] ">Narayan 2017</a>). For details on differences between the protocol and review see '<a href="#CD012838-sec-0118">Differences between protocol and review</a>' section. We included randomised controlled trials except cross‐over trials and cluster randomised trials. We excluded all other study designs. </p> </section> <section id="CD012838-sec-0040"> <h4 class="title">Types of participants</h4> <p>We included participants with locally advanced (&gt;T2) or metastatic (M1) urothelial carcinoma of the bladder as determined by cross‐sectional imaging or confirmed by biopsy, or both, whose disease progressed during or following platinum‐containing chemotherapy (synonymous with second‐/third‐/fourth‐line therapy). We did not include participants receiving pembrolizumab as first‐line therapy. </p> </section> <section id="CD012838-sec-0041"> <h4 class="title">Types of interventions</h4> <p>This review focused on pembrolizumab (synonyms: MK‐3475, lambrolizumab, Keytruda). We investigated the following comparisons of experimental intervention versus comparator intervention. </p> <section id="CD012838-sec-0042"> <h5 class="title">Experimental interventions</h5> <p> <ul id="CD012838-list-0001"> <li> <p>Pembrolizumab.</p> </li> </ul> </p> </section> <section id="CD012838-sec-0043"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD012838-list-0002"> <li> <p>Second‐/third‐/fourth‐line chemotherapy.</p> </li> </ul> </p> </section> <section id="CD012838-sec-0044"> <h5 class="title">Comparison</h5> <p> <ul id="CD012838-list-0003"> <li> <p>Pembrolizumab versus second‐/third‐/fourth‐line chemotherapy.</p> </li> </ul> </p> <p>Concomitant interventions have to be the same in the experimental and comparator groups to establish fair comparisons. We planned inclusion of all studies comparing pembrolizumab with second‐/third‐/fourth‐line chemotherapy, irrespective of dose, route, frequency or duration. </p> </section> </section> <section id="CD012838-sec-0045"> <h4 class="title">Types of outcome measures</h4> <p>We predefined the following outcome measures.</p> <section id="CD012838-sec-0046"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012838-list-0004"> <li> <p>Time to death from any cause as measured from the time of random sequence generation to time of death irrespective of cause (time‐to‐event outcome). </p> </li> <li> <p>Quality of life as measured by validated instruments (continuous outcome).</p> </li> </ul> </p> </section> <section id="CD012838-sec-0047"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012838-list-0005"> <li> <p>Time to progression as measured from the time of random sequence generation to the time of first confirmed progression, relapse, or death from urothelial carcinoma (time‐to‐event outcome). </p> </li> <li> <p>Response rate (patients with no complete or partial response), measured as complete response or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (categorical outcome; <a href="./references#CD012838-bbs2-0012" title="EisenhauerEA , TherasseP , BogaertsJ , SchwartzLH , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009; Vol. 45, issue 2:228‐47. ">Eisenhauer 2009</a>). </p> </li> <li> <p>Treatment‐related mortality (dichotomous outcome).</p> </li> <li> <p>Discontinuation due to adverse events (any grade according to the Common Terminology Criteria for Adverse Events (CTCAE)), measured from the time of random sequence generation to discontinuation of therapy because of an adverse event (dichotomous outcome). </p> </li> <li> <p>Rate of serious adverse events (grade 3, 4, or 5 according to the CTCAE), such as pruritus, fatigue, diarrhoea, anaemia, constipation, neuropathy, neutropenia, alopecia, hypo‐/hyperthyroidism, pneumonitis, colitis, nephritis, skin reaction, thyroiditis, adrenal insufficiency, myositis, hypophysitis, or cardiovascular events (dichotomous outcome). </p> </li> </ul> </p> <p>If we were unable to retrieve the necessary information to analyse time‐to‐event outcomes, we planned to assess the number of events per total number of included patients for dichotomised outcomes at 6 months and 12 months. </p> <section id="CD012838-sec-0048"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p>We presented a 'Summary of findings' table reporting the following outcomes listed according to priority. Outcome priority was determined by review authors providing content expertise (FK, PD). </p> <p> <ul id="CD012838-list-0006"> <li> <p>Time to death from any cause (reported as overall mortality at 12 months).</p> </li> <li> <p>Quality of life.</p> </li> <li> <p>Response rate (complete or partial response radiographically).</p> </li> <li> <p>Treatment‐related mortality.</p> </li> <li> <p>Discontinuations due to adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012838-sec-0049"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted a Cochrane Rapid Review. For details on the search strategy see the <a href="#CD012838-sec-0110">Appendices</a> section. </p> <section id="CD012838-sec-0050"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources.</p> <p> <ul id="CD012838-list-0007"> <li> <p>Databases of medical literature:</p> <ul id="CD012838-list-0008"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; June 2018);</p> </li> <li> <p>MEDLINE (via PubMed; January 2000 to June 2018).</p> </li> </ul> </li> </ul> <ul id="CD012838-list-0009"> <li> <p>Databases of ongoing trials:</p> </li> </ul> <ul class="plain" id="CD012838-list-0010"> <li> <ul id="CD012838-list-0011"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; 2000 to June 2018); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>; 2000 to June 2018). </p> </li> </ul> </li> </ul> </p> <p>This being an expedited, rapid review, we limited our search to published studies and to the use of English as the language of publication. We did not search the databases and web‐sites of institutions, such as pharmaceutical organisations, agencies, and societies. We began the search in 2000 because the underlying mechanism of action of tumour immunotherapy by PD‐L1 blockade was first reported in 2002 (<a href="./references#CD012838-bbs2-0027" title="IwaiY , IshidaM , TanakaY , OkazakiT , HonjoT , MinatoN . Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade. Proceedings of the National Academy of Sciences of the United States of America2002;99(19):12293‐7. ">Iwai 2002</a>). </p> </section> <section id="CD012838-sec-0051"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all identified trials, relevant review articles, and current treatment guidelines for further literature (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>; <a href="./references#CD012838-bbs2-0029" title="Leitlinienprogramm Onkologie, DeutscheKrebsgesellschaft , DeutscheKrebshilfe , AWMF . S3 ‐ Guideline for early detection, diagnosis, therapy and aftercare for bladder cancer [S3 ‐ Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms]. leitlinienprogramm‐onkologie.de/Harnblasenkarzinom.92.0.html (accessed 1 October 2017). ">Leitlinienprogramm Onkologie</a>), but as this is an expedited review, did not contact experts in the field, drug manufacturers, or regulatory agencies for additional information on unpublished trials. </p> </section> </section> <section id="CD012838-sec-0052"> <h3 class="title" id="CD012838-sec-0052">Data collection and analysis</h3> <section id="CD012838-sec-0053"> <h4 class="title">Selection of studies</h4> <p>We used reference management software to identify and remove potential duplicate records (<a href="./references#CD012838-bbs2-0013" title="Thomson Reuters. EndNote X5. Version X5. Thomson Reuters, 2011. ">Endnote 2011</a>). Two review authors (VN, FK) independently scanned the abstract, title, or both, of the remaining records retrieved and investigated all potentially relevant records as full text, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies using Covidence software (<a href="./references#CD012838-bbs2-0010" title="Veritas Health Innovation. Covidence. Version accessed 28 August 2017. Melbourne, Australia: Veritas Health Innovation, 2017. ">Covidence</a>). We resolved discrepancies through consensus or consultation with a third review author (PD). We documented reasons for the exclusion of studies that may have reasonably been expected to be included in the review in a 'Characteristics of excluded studies' table. We present an adapted Preferred Reporting Items for Systematic Reviews and Meta‐Analyses ((PRISMA) flow diagram showing the process of study selection (<a href="./references#CD012838-bbs2-0031" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> </section> <section id="CD012838-sec-0054"> <h4 class="title">Data extraction and management</h4> <p>For studies that fulfilled the inclusion criteria, one review author (FK) extracted key participant and intervention characteristics using a data extraction form based on the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012838-bbs2-0020" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). A second review author checked data entry (VN). We resolved disagreements by consensus or, when required, by consultation with a third review author (PD). </p> <p>We extracted the following information.</p> <p> <ul id="CD012838-list-0012"> <li> <p>Study design and number of study centres.</p> </li> <li> <p>Run‐in period.</p> </li> <li> <p>Participant inclusion and exclusion criteria.</p> </li> <li> <p>Participant details, baseline demographics such as visceral/liver metastases, age or ECOG (Eastern Cooperative Oncology Group) performance status. </p> </li> <li> <p>The number of participants by study/study arm.</p> </li> <li> <p>Details of relevant experimental and comparator interventions such as dose, route, frequency, and duration. </p> </li> <li> <p>Definitions of primary and secondary outcomes, and method and timing of outcome measurement.</p> </li> <li> <p>Study funding sources</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We attempted to provide information, including trial identifier, about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' table. We attempted to contact authors of included studies to obtain key missing data when needed. </p> <p>We extracted outcome data relevant to this review as needed for the calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events per total number of included participants to enable the population of a 2 x 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations or the data necessary to calculate this information. For time‐to‐event outcomes, we attempted to obtain hazard ratios (HRs) with corresponding measures of variance or the data necessary to calculate this information. </p> <section id="CD012838-sec-0055"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>For duplicate publications, companion documents, or multiple reports of a primary trial, we maximised the information yield by collating all available data and used the most complete data set aggregated across all known publications. We listed multiple reports of the primary trial as secondary references under the study identifier of the included trial. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> <section id="CD012838-sec-0056"> <h5 class="title">Data from clinical trial registers</h5> <p>We extracted data from any included studies published in clinical trial registers.</p> </section> </section> <section id="CD012838-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author assessed the risk of bias in each included study (FK), and a second review author checked the data entry (VN). We resolved disagreements by consensus, or by consultation with a third review author (PD). </p> <p>We assessed the risk of bias in included randomised controlled trials using the Cochrane 'Risk of bias' tool (<a href="./references#CD012838-bbs2-0021" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We assessed the following domains. </p> <p> <ul id="CD012838-list-0013"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged the study as being at 'low risk', 'high risk', or 'unclear risk' for each domain and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012838-bbs2-0021" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We present a 'Risk of bias' graph to illustrate these findings. </p> <p>For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessment), we evaluated the risk of bias separately for each outcome (<a href="./references#CD012838-bbs2-0025" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>), but grouped outcomes as appropriate, as detailed below. </p> <p>With regard to performance bias, we judged outcomes as being similarly susceptible to performance bias and rated them as one group. </p> <p>We defined the following endpoints as subjective outcomes in terms of susceptibility to detection bias and rated them as one group. </p> <p> <ul id="CD012838-list-0014"> <li> <p>Quality of life.</p> </li> <li> <p>Progression‐free survival.</p> </li> <li> <p>Response rate (patients with complete or partial response).</p> </li> <li> <p>Treatment‐related mortality.</p> </li> <li> <p>Rate of serious adverse events.</p> </li> </ul> </p> <p>We defined the following endpoint as an objective outcome in terms of susceptibility to detection bias. </p> <p> <ul id="CD012838-list-0015"> <li> <p>Overall survival.</p> </li> </ul> </p> <p>We assessed attrition bias (incomplete outcome data) on an outcome‐specific basis, and grouped outcomes with like judgements when reporting our findings in the 'Risk of bias' tables. </p> <p>We summarised the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome. </p> </section> <section id="CD012838-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as a risk ratio (RR) with 95% confidence interval (CI). For continuous outcomes measured on the same scale, we estimated the intervention effect using the mean difference (MD) with 95% CI. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but using different measurement scales, we planned to calculate the standardised mean difference (SMD). We expressed time‐to‐event data as HRs with 95% CIs or used an indirect estimation method if HRs were not given (<a href="./references#CD012838-bbs2-0036" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. [PUBMED: 9921604] ">Parmar 1998</a>; <a href="./references#CD012838-bbs2-0045" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. [PUBMED: 17555582] ">Tierney 2007</a>). </p> </section> <section id="CD012838-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. If we had identified trials with more than two intervention groups for inclusion in the review, we would have handled these in accordance with guidance provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012838-bbs2-0022" title="HigginsJP , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011c</a>). </p> </section> <section id="CD012838-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We planned to obtain missing data from study authors, if feasible, and planned to perform intention‐to‐treat analyses if data were available; we otherwise performed analyses as treated and would have indicated this as a potential source of bias. We investigated attrition rates (e.g. drop‐outs, losses to follow up, and withdrawals) and critically appraised issues of missing data. We did not plan to impute missing data. </p> </section> <section id="CD012838-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity; however, we included only one randomised controlled trial and therefore assessment of heterogeneity was not possible. </p> </section> <section id="CD012838-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>We obtained the study protocol of the included randomised controlled trial to assess for selective outcome reporting. We also searched for completed but not reported trials in trial registers (ClinicalTrials.gov; WHO ICTRP). </p> </section> <section id="CD012838-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We presented data from the included randomised controlled trial using Review Manager software (<a href="./references#CD012838-bbs2-0038" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>) in accordance with the guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012838-bbs2-0020" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). For dichotomous outcomes we used the Mantel‐Haenszel method; for continuous outcomes we used the inverse variance method; and for time‐to‐event outcomes we used the generic inverse variance method. </p> <p>For the analyses of individual serious adverse events with very low events rates we used Peto's odds ratio method as suggested by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012838-bbs2-0023" title="DeeksJJ , HigginsJP , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011d</a>). </p> </section> <section id="CD012838-sec-0064"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to potentially introduce clinical heterogeneity, and carried out the following subgroup analyses to test for subgroup differences in Review Manager (<a href="./references#CD012838-bbs2-0038" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <p> <ul id="CD012838-list-0016"> <li> <p>Performance status (Eastern Cooperative Oncology Group (ECOG) 0 or 1 versus <b>≥</b> 2). </p> </li> <li> <p>Time since last chemotherapy administration (&lt; three months versus <b>≥</b> three months). </p> </li> <li> <p>Degree of pretreatment (second‐ versus third‐ versus fourth‐line or more).</p> </li> <li> <p>PDL‐1 tumour expression status (positive versus negative).</p> </li> </ul> </p> </section> <section id="CD012838-sec-0065"> <h4 class="title">Sensitivity analysis</h4> <p>We only identified one randomised controlled trial and were therefore not able to perform sensitivity analyses. </p> <section id="CD012838-sec-0066"> <h5 class="title">'Summary of findings' table</h5> <p>We present the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account five criteria related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity (directness of results; <a href="./references#CD012838-bbs2-0018" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , SchünemannHJ , et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.)2008;336(7651):995‐8. '>Guyatt 2008</a>)<i>.</i> We used the GRADEpro Guideline Development Tool to assess the quality of the evidence, according to the recommendations of the GRADE working group (<a href="./references#CD012838-bbs2-0016" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 1 February 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT</a>). Two review authors (FK, PD) independently rated the certainty of evidence for each outcome as 'high', 'moderate', 'low', or 'very low'; we resolved discrepancies by consensus or, when needed, by the arbitration of a third review author (NS). We present a summary of the evidence for the main outcomes in a 'Summary of findings' table; these tables provide key information about the best estimate of the magnitude of the effect in relative terms and present absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in the effect estimates for each outcome (<a href="./references#CD012838-bbs2-0019" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>; <a href="./references#CD012838-bbs2-0042" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>). If meta‐analysis was not possible, we planned to present results in a narrative 'Summary of findings' table. </p> <p>See <a href="#CD012838-sec-0045">Types of outcome measures</a> for the outcomes included in the 'Summary of findings' table. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012838-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012838-sec-0067"></div> <section id="CD012838-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD012838-sec-0069"> <h4 class="title">Results of the search</h4> <p>We identified 352 records following our database search, and after screening by title and abstract, evaluated 13 full‐text articles for eligibility. Only one study, reported in six records, ultimately met the inclusion criteria for assessment of the study question (for details see '<a href="#CD012838-fig-0001">Figure 1</a>'). Four of the six records were additionally found by handsearching or screening of reference lists. We did not identify any completed but not reported trials. </p> <div class="figure" id="CD012838-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012838-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012838-sec-0070"> <h4 class="title">Included studies</h4> <p>We identified one randomised controlled trial (<a href="./references#CD012838-bbs2-0001" title="BellmuntJ , SonpavdeG , WitR , ChoueiriTK , Siefker‐RadtkeAO , PlimackER , et al. KEYNOTE‐045: randomized phase 3 trial of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. Journal of Clinical Oncology2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.tps4571] BellmuntJ , deWitR , VaughnDJ , FradetY , LeeJ‐L , FongL , et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. New England Journal of Medicine2017;376(11):1015‐26. [DOI: 10.1056/NEJMoa1613683] DeWitR , BajorinDF , BellmuntJ , FradetY , LeeJ‐L , FongL . Health‐related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE‐045. Journal of Clinical Oncology2017;35(15 Suppl):4530. [DOI: 10.1200/JCO.2017.35.15_suppl.4530] MerckSharp , DohmeCorp . A study of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK‐3475‐045/KEYNOTE‐045). clinicaltrials.gov/ct2/show/NCT02256436 (accessed 1 November 2017). QuinnD , BellmuntJ , WitR , VaughnDJ , FradetY , LeeJL , et al. Keynote‐045: open‐label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. Asia‐Pacific Journal of Clinical Oncology2017; Vol. 13, issue Suppl S1:35. VaughnDJ , BellmuntJ , FradetY , LeeJL , FongL , VogelzangNJ , et al. Health‐Related Quality‐of‐Life Analysis From KEYNOTE‐045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology2018;36(16):1579‐1587. ">Bellmunt 2017</a>). For details see '<a href="./references#CD012838-sec-0121" title="">Characteristics of included studies</a>' table, <a href="#CD012838-tbl-0002">Table 1</a>, and <a href="#CD012838-tbl-0003">Table 2</a>. </p> <div class="table" id="CD012838-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial period (year to year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ethnic groups (%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bellmunt 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: pembrolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Median 14.1 months (for quality of life: from randomisation to week 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Participants with advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2014‐2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: paclitaxel or docetaxel or vinflunine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>C</b> : comparator; <b>I</b> : intervention; <b>‐</b>: not reported. </p> </div> </div> <div class="table" id="CD012838-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant disposition</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N screened/eligible</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N ITT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N analysed for overall survival, progression‐frees survival, and response rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N analysed for quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N analysed for treatment‐related mortality, discontinuation due to adverse events, and adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Bellmunt 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: Pembrolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Median 14.1 months (9.9‐22.1; for quality of life: from randomisation to week 15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: Paclitaxel or docetaxel or vinflunine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>521</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Grand total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="3" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>272</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All interventions and comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>542</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or, if not available, duration of intervention. </p> <p><b>C</b> : comparator; <b>I</b> : intervention; <b>ITT</b>: intention‐to‐treat. </p> </div> </div> <p>The included trial compared pembrolizumab monotherapy with chemotherapy (paclitaxel or vinflunine or docetaxel) for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. 748 participants were screened for enrolment in 120 sites in 29 countries (Australia, Austria, Belgium, Canada, Chile, Denmark, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Republic of Korea, Netherlands, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Singapore, Spain, Sweden, Taiwan, Turkey, United Kingdom, and United States). Between November 2014 and November 2015, 542 participants were randomly assigned in this trial that was sponsored by the producer of pembrolizumab. The median duration of follow‐up was 14.1 months (range 9.9 to 22.1 months). The majority of participants had an ECOG performance status of 0 to 1 (pembrolizumab n = 262/270; chemotherapy n = 264/272) and a visceral disease (pembrolizumab n = 240/270; chemotherapy n = 233/272). Liver metastases were evident in 33.7% to 35.1% of participants (pembrolizumab n = 91/270; chemotherapy n = 95/272). </p> </section> <section id="CD012838-sec-0071"> <h4 class="title">Excluded studies</h4> <p>For details see '<a href="./references#CD012838-sec-0122" title="">Characteristics of excluded studies</a>' section. </p> <p>We excluded seven studies after assessing for eligibility (wrong comparator, n = 1; first‐line therapy, n = 2; comments to other articles/letters, n = 3; wrong intervention, n = 1). </p> </section> </section> <section id="CD012838-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>For details see '<a href="./references#CD012838-sec-0121" title="">Characteristics of included studies</a>' with 'Risk of bias' table, '<a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>' and '<a href="#CD012838-fig-0002">Figure 2</a>' and '<a href="#CD012838-fig-0003">Figure 3</a>'. </p> <div class="figure" id="CD012838-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012838-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012838-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012838-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012838-sec-0073"> <h4 class="title">Allocation</h4> <p>Random sequence generation and allocation concealment were performed adequately, and we judged this study to be at low risk of selection bias. </p> </section> <section id="CD012838-sec-0074"> <h4 class="title">Blinding</h4> <section id="CD012838-sec-0075"> <h5 class="title">Performance bias</h5> <p>Participants and personnel were not blinded but we are uncertain whether this could have plausibly effected overall survival; we therefore rated the risk of bias as unclear for this outcome. </p> <p>All others outcomes (quality of life, time to progression, response rate, discontinuation due to adverse events and serious adverse events) were judged to be potentially susceptible to co‐interventions, thereby making blinding important; we rated the risk of bias as high risk. </p> </section> <section id="CD012838-sec-0076"> <h5 class="title">Detection bias</h5> <p>Blinding of outcome assessors is not relevant to overall survival; we rated the risk of bias as low. The assessors of radiographical responses were reported to be blinded; we rated the risk of bias as low also. </p> <p>All others outcomes (quality of life, time to progression, discontinuation due to adverse events and serious adverse events) which involve judgments on the part of the unblinded participants or investigators, or both, we judged to be potentially susceptible to detection bias, thereby making blinding important; we rated the risk of bias as high risk. </p> </section> </section> <section id="CD012838-sec-0077"> <h4 class="title">Incomplete outcome data</h4> <p>All participants who were randomised were included in the analysis for overall survival, progression‐free survival, and response rate. Attrition was less than 10% in either group for all other outcomes. We judged the risk of attrition bias as low for all outcomes. </p> </section> <section id="CD012838-sec-0078"> <h4 class="title">Selective reporting</h4> <p>A protocol was available and the reported outcomes and their analyses in the completed study corresponded to how these had been planned. However, quality of life was not listed as a predefined outcome in the ClinicalTrials.gov registry (NCT02256436). We therefore assigned a judgment of unclear risk of reporting bias for the outcome of quality of life. </p> </section> <section id="CD012838-sec-0079"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential sources of bias were identified.</p> </section> </section> <section id="CD012838-sec-0080"> <h3 class="title" id="CD012838-sec-0080">Effects of interventions</h3> <p>See: <a href="./full#CD012838-tbl-0001"><b>Summary of findings for the main comparison</b> Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review</a> </p> <section id="CD012838-sec-0081"> <h4 class="title">1. Pembrolizumab versus chemotherapy</h4> <section id="CD012838-sec-0082"> <h5 class="title">1.1 Primary outcomes</h5> <section id="CD012838-sec-0083"> <h6 class="title">1.1.1. Time to death from any cause</h6> <p>Pembrolizumab probably extends time to death from any cause (HR 0.73, 95% CI 0.59 to 0.90; 1 study; 542 participants; median follow‐up 14.1 months; <a href="./references#CD012838-fig-0007" title="">Analysis 1.1</a>; <a href="#CD012838-fig-0004">Figure 4</a>; moderate certainty evidence). This corresponds to 695 deaths per 1000 participants with chemotherapy and 115 fewer (191 fewer to 38 fewer) deaths per 1000 participants with pembrolizumab. We downgraded the certainty of the evidence by one level for imprecision (<a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD012838-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.1 Overall survival." data-id="CD012838-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.1 Overall survival. </p> </div> </div> </div> </section> <section id="CD012838-sec-0084"> <h6 class="title">1.1.2. Quality of life</h6> <p>Quality of life (change from baseline to week 15) was not listed as a predefined outcome in the ClinicalTrials.gov registry (NCT02256436). Quality of life was assessed with the Core Quality of Life Questionnaire (QLQ‐C30). Quality of life scores from baseline to week 15 were stable for pembrolizumab, while they decreased with chemotherapy, but the difference did not quite meet the threshold of a minimal clinically important difference of 10 (MD 9.05, 95% CI 4.61 to 13.50; 1 study; 520 participants; <a href="./references#CD012838-fig-0008" title="">Analysis 1.2</a>; <a href="#CD012838-fig-0005">Figure 5</a>; low quality evidence). A high score represents better quality of life on this scale. We downgraded the certainty of evidence two levels for study limitations and imprecision (<a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD012838-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.2 Quality of life (change from baseline to week 15)." data-id="CD012838-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.2 Quality of life (change from baseline to week 15). </p> </div> </div> </div> </section> </section> <section id="CD012838-sec-0085"> <h5 class="title">1.2. Secondary outcomes</h5> <section id="CD012838-sec-0086"> <h6 class="title">1.2.1. Time to progression</h6> <p>Pembolizumab may have little or no effect on time to progression (HR 0.98, 95% CI 0.81 to 1.19; 1 study; 542 participants; median follow‐up 14.1 months; <a href="./references#CD012838-fig-0009" title="">Analysis 1.3</a>). This corresponds to three fewer (42 fewer to 24 more) progression events per 1000 participants at 12‐month follow‐up. We downgraded the certainty of evidence for imprecision. </p> </section> <section id="CD012838-sec-0087"> <h6 class="title">1.2.2. Response rate (partial and complete response)</h6> <p>Response rate (partial or complete radiologic response to therapy) was probably improved slightly with pembrolizumab (RR 1.85, 95% CI 1.24 to 2.77; 1 study; 542 participants; median follow‐up 14.1 months; <a href="./references#CD012838-fig-0010" title="">Analysis 1.4</a>; <a href="#CD012838-fig-0006">Figure 6</a>; moderate quality evidence). This corresponds to 114 respondents per 1000 participants with chemotherapy and 97 more (27 more to 202 more) respondents per 1000 participants with pembrolizumab. Certainty of evidence was judged to be moderate (downgraded one level for imprecision; <a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD012838-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.8 Serious adverse events (irrespective of attribution to treatment)." data-id="CD012838-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.8 Serious adverse events (irrespective of attribution to treatment). </p> </div> </div> </div> <p><b>1.2.3. Treatment‐related mortality</b> </p> <p>Pembrolizumab may have little or no impact on treatment‐related mortality (HR 0.96, 95% CI 0.24 to 3.79; 1 study; 521 participants; median follow‐up 14.1 months; <a href="./references#CD012838-fig-0011" title="">Analysis 1.5</a>). This corresponds to one less treatment‐related death per 1000 participants (95% CI: 12 fewer to 44 more). The certainty of evidence was judged to be low, we downgraded two levels for study limitations and imprecision; <a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD012838-sec-0088"> <h6 class="title">1.2.4. Discontinuation due to adverse events (any grade)</h6> <p>Pembrolizumab may have little of no effect on discontinuations due to adverse events (RR 0.66, 95% CI 0.39 to 1.10; 1 study; 521 participants; median follow‐up 14.1 months; <a href="./references#CD012838-fig-0012" title="">Analysis 1.6</a>). This corresponds to 54 fewer discontinuations per 1000 participants (95% CI 79 fewer to 7 fewer). We downgraded the certainty of evidence for study limitations and imprecision (<a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD012838-sec-0089"> <h6 class="title">1.2.5. Serious adverse events (irrespective of attribution to treatment)</h6> <p>We included adverse events data of grade 3, 4, or 5 according to CTCAE regardless of attribution to treatment by the investigator. Pembrolizumab may reduce serious adverse events (RR 0.83, 95 CI 0.72 to 0.97; low certainty evidence <a href="./references#CD012838-fig-0013" title="">Analysis 1.7</a>). This corresponds to 107 fewer serious averse events per 1000 participants (95% CI 19 fewer to 176 fewer). We downgraded two levels for study limitations and imprecision. </p> <section id="CD012838-sec-0090"> <p><b><i>Individual serious adverse events (any adverse events of grade 3, 4, or 5 according to CTCAE)</i> </b></p> <p>Pembrolizumab probably decreases the rate of neutropenia (OR 0.11, 95% CI 0.06 to 0.22; 1 study; 521 participants; <a href="./references#CD012838-fig-0014" title="">Analysis 1.8</a>; <a href="#CD012838-fig-0006">Figure 6</a>). We are uncertain whether pembrolizumab improves or reduces the rate of pruritus, fatigue, diarrhoea, anaemia, constipation, peripheral sensory neuropathy, alopecia, hypothyroidism, or skin reaction as the certainty of the evidence is limited by imprecision, as well as performance and detection bias. </p> <p>We identified no adverse events data regardless of attribution to treatment by the investigators for pneumonitis (only treatment‐related events were reported: pembrolizumab 6/266 versus chemotherapy 0/255), hyperthyroidism (only treatment‐related events were reported: pembrolizumab 0/266 versus chemotherapy 0/255), colitis (only treatment‐related events were reported: pembrolizumab 3/266 vs. chemotherapy 0/255), nephritis (only treatment‐related events were reported: pembrolizumab 2/266 versus chemotherapy 0/255), thyroiditis (only treatment‐related events were reported: pembrolizumab 0/266 versus chemotherapy 0/255), adrenal insufficiency (only treatment‐related events were reported: pembrolizumab 1/266 versus chemotherapy 0/255), and myositis (only treatment‐related events were reported: pembrolizumab 0/266 versus chemotherapy 1/255). </p> <p>We identified no adverse events data for hypophysitis and cardiovascular events.</p> </section> </section> </section> <section id="CD012838-sec-0091"> <h5 class="title">Subgroup analyses</h5> <section id="CD012838-sec-0092"> <h6 class="title">Preplanned subgroup analyses</h6> <p>We performed preplanned subgroup analyses with regard to overall survival.</p> <section id="CD012838-sec-0093"> <p><b>Performance status (ECOG 0 or 1 versus ≥ 2)</b></p> <p>For details see <a href="./references#CD012838-fig-0015" title="">Analysis 2.1</a>. Of 542 participants, 526 had an ECOG 0 to 1 (262 in the pembrolizumab group, 264 in the chemotherapy group); and 6 had an ECOG <b>≥</b> 2 (2 in the pembrolizumab group, 4 in the chemotherapy group; 10 participants had missing data). We did not find evidence for subgroup differences (ECOG 0 to 1 versus <b>≥</b> 2; P = 0.66). </p> </section> <section id="CD012838-sec-0094"> <p><b>Time since last chemotherapy administration (&lt; three months versus ≥ three months)</b></p> <p>For details see <a href="./references#CD012838-fig-0016" title="">Analysis 2.2</a>. Of 542 participants, 207 received chemotherapy for less than three months (103 in the pembrolizumab group, 104 in the chemotherapy group) and 333 received chemotherapy for greater than or equal to three months (166 in the pembrolizumab group, 167 in the chemotherapy group). We did not find evidence for subgroup differences (last chemotherapy administration &lt; three months versus <b>≥</b> three months; P = 0.35). </p> </section> <section id="CD012838-sec-0095"> <p><b>Degree of pretreatment (second‐ versus third‐ versus fourth‐line or more)</b></p> <p>For details see <a href="./references#CD012838-fig-0017" title="">Analysis 2.3</a>. Of 542 participants, 84 had adjuvant or neoadjuvant chemotherapy, 340 had one prior treatment for metastatic disease, and 115 had two prior treatments for metastatic disease. We did not find evidence for subgroup differences (degree of pretreatment; P = 0.79). </p> </section> <section id="CD012838-sec-0096"> <p><b>PD‐L1 tumour expression status (positive versus negative; 1% cutoff)</b></p> <p>For details see <a href="./references#CD012838-fig-0018" title="">Analysis 2.4</a>. Of 298 participants, 184 had a tumour PD‐L1 combined positive score of less than one per cent (negative according to our definition) and 142 of 230 participants had a positive score greater than or equal to one per cent (positive according to our definition). We did not find evidence for subgroup differences (P = 0.11). </p> </section> </section> <section id="CD012838-sec-0097"> <h6 class="title">Post‐hoc included subgroup analyses</h6> <p>We also included further not‐preplanned subgroup analyses (see <a href="./references#CD012838-fig-0019" title="">Analysis 3.1</a> ‐ <a href="./references#CD012838-fig-0030" title="">Analysis 3.12</a>). </p> <section id="CD012838-sec-0098"> <p><b>Smoking status</b></p> <p>For details see <a href="./references#CD012838-fig-0021" title="">Analysis 3.3</a>. Of 542 participants, 67 were current smokers (29 in the pembrolizumab group, 38 in the chemotherapy group), 284 were former smokers (136 in the pembrolizumab group, 148 in the chemotherapy group), and 187 never smoked (104 in the pembrolizumab group, 83 in the chemotherapy group). We found heterogeneity between these two subgroups (I² = 75%). The test for subgroup differences showed a difference between the subgroups (P = 0.02). Overall survival was probably more improved with pembrolizumab in current smokers (HR 0.32, 95% CI 0.15‐0.68) compared to former smokers (HR 0.71, 95% CI 0.52 to 0.97) or participants who had never smoked (HR 1.06, 95% CI 0.72 to 1.55). </p> <p>For all other subgroup analyses, the test for subgroup differences showed no difference (P &gt; 0.05; <a href="./references#CD012838-fig-0019" title="">Analysis 3.1</a>; <a href="./references#CD012838-fig-0020" title="">Analysis 3.2</a>; <a href="./references#CD012838-fig-0022" title="">Analysis 3.4</a>; <a href="./references#CD012838-fig-0023" title="">Analysis 3.5</a>; <a href="./references#CD012838-fig-0024" title="">Analysis 3.6</a>; <a href="./references#CD012838-fig-0025" title="">Analysis 3.7</a>; <a href="./references#CD012838-fig-0026" title="">Analysis 3.8</a>; <a href="./references#CD012838-fig-0027" title="">Analysis 3.9</a>; <a href="./references#CD012838-fig-0028" title="">Analysis 3.10</a>; <a href="./references#CD012838-fig-0029" title="">Analysis 3.11</a>; <a href="./references#CD012838-fig-0030" title="">Analysis 3.12</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012838-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012838-sec-0099"></div> <section id="CD012838-sec-0100"> <h3 class="title" id="CD012838-sec-0100">Summary of main results</h3> <p>We identified one randomised controlled trial with 542 participants that compared pembrolizumab monotherapy with chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. Pembrolizumab probably extends time to death from any cause (moderate certainty of evidence) and may improve quality of life slightly. It may not impact treatment related mortality, but may reduce discontinuations due to adverse events and serious adverse events. </p> </section> <section id="CD012838-sec-0101"> <h3 class="title" id="CD012838-sec-0101">Overall completeness and applicability of evidence</h3> <p>This Cochrane Rapid Review is based on only one randomised controlled trial (<a href="./references#CD012838-bbs2-0001" title="BellmuntJ , SonpavdeG , WitR , ChoueiriTK , Siefker‐RadtkeAO , PlimackER , et al. KEYNOTE‐045: randomized phase 3 trial of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. Journal of Clinical Oncology2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.tps4571] BellmuntJ , deWitR , VaughnDJ , FradetY , LeeJ‐L , FongL , et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. New England Journal of Medicine2017;376(11):1015‐26. [DOI: 10.1056/NEJMoa1613683] DeWitR , BajorinDF , BellmuntJ , FradetY , LeeJ‐L , FongL . Health‐related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE‐045. Journal of Clinical Oncology2017;35(15 Suppl):4530. [DOI: 10.1200/JCO.2017.35.15_suppl.4530] MerckSharp , DohmeCorp . A study of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK‐3475‐045/KEYNOTE‐045). clinicaltrials.gov/ct2/show/NCT02256436 (accessed 1 November 2017). QuinnD , BellmuntJ , WitR , VaughnDJ , FradetY , LeeJL , et al. Keynote‐045: open‐label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. Asia‐Pacific Journal of Clinical Oncology2017; Vol. 13, issue Suppl S1:35. VaughnDJ , BellmuntJ , FradetY , LeeJL , FongL , VogelzangNJ , et al. Health‐Related Quality‐of‐Life Analysis From KEYNOTE‐045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology2018;36(16):1579‐1587. ">Bellmunt 2017</a>). However, the included study evaluated the drug pembrolizumab in a clinically important population seen in daily clinical practice. The participants and interventions conformed to the review question and the study reported on all predefined outcomes. Our patient important co‐primary outcome quality of life was not listed as a predefined outcome in the ClinicalTrials.gov registry (NCT02256436), but results were presented in abstract form at ASCO GU 2017 conference. No quality of life data were presented in the published manuscript. </p> <p>The included study analysed only a few relevant adverse events, and the confidence intervals for adverse events are wide, leading to the presumption that current evidence is limited by imprecision. Further research including post‐market phase IV studies appear necessary for the evaluation of safety and rare adverse events. </p> <p>In a letter to the editor regarding <a href="./references#CD012838-bbs2-0001" title="BellmuntJ , SonpavdeG , WitR , ChoueiriTK , Siefker‐RadtkeAO , PlimackER , et al. KEYNOTE‐045: randomized phase 3 trial of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. Journal of Clinical Oncology2015 [Epub ahead of print]; Vol. 33, issue 15 Suppl. [DOI: 10.1200/jco.2015.33.15_suppl.tps4571] BellmuntJ , deWitR , VaughnDJ , FradetY , LeeJ‐L , FongL , et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. New England Journal of Medicine2017;376(11):1015‐26. [DOI: 10.1056/NEJMoa1613683] DeWitR , BajorinDF , BellmuntJ , FradetY , LeeJ‐L , FongL . Health‐related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE‐045. Journal of Clinical Oncology2017;35(15 Suppl):4530. [DOI: 10.1200/JCO.2017.35.15_suppl.4530] MerckSharp , DohmeCorp . A study of pembrolizumab (MK‐3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK‐3475‐045/KEYNOTE‐045). clinicaltrials.gov/ct2/show/NCT02256436 (accessed 1 November 2017). QuinnD , BellmuntJ , WitR , VaughnDJ , FradetY , LeeJL , et al. Keynote‐045: open‐label, phase 3 study of pembrolizumab versus investigator's choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer. Asia‐Pacific Journal of Clinical Oncology2017; Vol. 13, issue Suppl S1:35. VaughnDJ , BellmuntJ , FradetY , LeeJL , FongL , VogelzangNJ , et al. Health‐Related Quality‐of‐Life Analysis From KEYNOTE‐045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology2018;36(16):1579‐1587. ">Bellmunt 2017</a>, Liang and Zhu remarked that the prespecified subgroup analysis for geographic region (East Asia versus non–East Asia and European Union versus non–European Union) was not reported, and raised concerns that variations in the geographic regions could affect the response to pembrolizumab (<a href="./references#CD012838-bbs2-0030" title="LiangF , ZhuJ . Pembrolizumab for advanced urothelial carcinoma. New England Journal of Medicine2017;376(23):2302. ">Liang 2017</a>). We were unable to address this concern. </p> <p>Additionally, no platinum‐containing second‐line chemotherapy (e.g. MVAC or gemcitabine plus cisplatin or carboplatin) was used to compare against pembrolizumab. Pembrolizumab was compared only with vinflunine, docetaxel, or paclitaxel, which may represent inferior regimens with reported minimal or non‐durable response rates. This may cast a more favourable light on the new agent, pembrolizumab. </p> <p>A detailed review of Kaplan‐Meier curves of pembrolizumab show characteristics that are noteworthy. Treatment response is seen as a parameter of uncertain value in check‐point‐blockade‐inhibition because it is observed that in certain participants there is a short progression initially after therapy start with objective response in the late therapy process and that certain participants will profit from continuing immunotherapy beyond first progression (<a href="./references#CD012838-bbs2-0024" title="HodiFS , HwuWJ , KeffordR , WeberJS , DaudA , HamidO , et al. Evaluation of immune‐related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. Journal of Clinical Oncology2016;34(13):1510‐7. ">Hodi 2016</a>). In the case of this study, second‐line chemotherapy appeared to be more superior to pembrolizumab in the first four months. Only afterwards did the survival curves cross and favour pembrolizumab. Additionally, only a certain fraction of participants appeared to benefit from pembrolizumab treatment; however, these individuals saw markedly long survival. There is further research necessary for improved selection of participants that will profit from pembrolizumab therapy. </p> </section> <section id="CD012838-sec-0102"> <h3 class="title" id="CD012838-sec-0102">Quality of the evidence</h3> <p>We rated the certainty of evidence about effects as moderate to low. Reasons for downgrading included concerns over performance and detection bias (due to lack of blinding) and imprecision. For details on certainty of evidence see <a href="./full#CD012838-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD012838-sec-0103"> <h3 class="title" id="CD012838-sec-0103">Potential biases in the review process</h3> <p>This Cochrane Rapid Review provides an overview of current evidence in a limited time frame and therefore uses streamlined systematic review methods for providing available evidence with shorter turnaround time. Nevertheless, this rapid review was performed with a broad search strategy in multiple biomedical databases and the evaluation of the literature and data extraction were performed by two independent review authors. While it is theoretically possible that additional studies may have been conducted but not yet published, or that additional studies may not have been identified, this is unlikely. </p> </section> <section id="CD012838-sec-0104"> <h3 class="title" id="CD012838-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review published by Wang and colleagues assessed immune‐related adverse events and included 46 studies representing 12,808 oncologic patients (including melanomas, Hodgkin lymphomas, urothelial carcinomas, breast cancers, non‐small cell lung cancers, renal cell carcinomas, colorectal cancers, and others; <a href="./references#CD012838-bbs2-0047" title="WangPF , ChenY , SongSY , WangTJ , JiWJ , LiSW , et al. Immune‐Related Adverse Events Associated with Anti‐PD‐1/PD‐L1 Treatment for Malignancies: A Meta‐Analysis. Frontiers in Pharmacology2017;8:730. ">Wang 2017</a>). They evaluated different immune‐checkpoint inhibitors including nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, and BMS‐936559. The authors found that in patients treated with PD‐1 signalling inhibitors, the overall incidence of immune‐related adverse events was 26.82% (I<sup>2</sup> = 92.80) in any grade and 6.10% (I<sup>2</sup> = 52.00) in severe grades (<a href="./references#CD012838-bbs2-0047" title="WangPF , ChenY , SongSY , WangTJ , JiWJ , LiSW , et al. Immune‐Related Adverse Events Associated with Anti‐PD‐1/PD‐L1 Treatment for Malignancies: A Meta‐Analysis. Frontiers in Pharmacology2017;8:730. ">Wang 2017</a>). However, interpretation of the data is limited because of missing control group evaluation data and high heterogeneity. </p> <p>A systematic review published by Rijinder et al. evaluated immune checkpoint inhibitors in urological cancers (<a href="./references#CD012838-bbs2-0040" title="RijndersM , deWitR , BoormansJL , LolkemaMP , van derVeldtAA . Systematic review of immune checkpoint inhibition in urological cancers. European Urology2017;72(3):411‐23. ">Rijnders 2017</a>). They similarly identified one study of pembrolizumab in second‐line treatment for urothelial carcinoma and concluded that this therapy may be safe and confers a survival benefit in advanced urothelial carcinoma (<a href="./references#CD012838-bbs2-0040" title="RijndersM , deWitR , BoormansJL , LolkemaMP , van derVeldtAA . Systematic review of immune checkpoint inhibition in urological cancers. European Urology2017;72(3):411‐23. ">Rijnders 2017</a>). However, there is no 'Risk of bias' assessment or grading of certainty of evidence provided. </p> <p>The guideline of the European Association of Urology recommends that vinflunine should be offered to patients progressing after platinum‐based combination chemotherapy for metastatic disease. However, vinflunine has not been approved by the FDA for this indication in the United States (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>). There is also a statement that it may be a reasonable strategy to re‐challenge former cisplatin‐sensitive patients if progression occurs at least six to twelve months after first‐line cisplatin‐based combination chemotherapy (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>). The bladder cancer guideline of the National Comprehensive Cancer Network recommends that consideration of checkpoint inhibitors must be integrated into therapeutic planning for all patients with locally advanced and metastatic disease and both guidelines recommend an enrolment of participants treated with immunotherapy in clinical trials (<a href="./references#CD012838-bbs2-0011" title="WitjesJA , CompératE , CowanNC , GakisG , HernándezV , LebretT , et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/ (accessed 1 October 2017). ">EAU 2017</a>; <a href="./references#CD012838-bbs2-0034" title="SpiessPE , AgarwalN , BangsR , BoorjianSA , BuyyounouskiMK , ClarkPE , et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network2017;15(10):1240‐67. ">NCCN Guideline 2017</a>). </p> <p>Also, the Institute for Quality and Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen), a German agency that is responsible for assessing the quality and efficacy of medical treatments, concluded that there is evidence of a considerable additional benefit with pembrolizumab (<a href="./references#CD012838-bbs2-0026" title="Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen(IQWiG) . Pembrolizumab (urothelial carcinoma) [Pembrolizumab (Urothelkarzinom)]. Institute for Quality and Efficiency in Health Care2017; Vol. Dossierbewertung A17‐46, issue Version 1.0:3‐9. ">IQWiG 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012838-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012838-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012838-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012838-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.1 Overall survival." data-id="CD012838-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.1 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.2 Quality of life (change from baseline to week 15)." data-id="CD012838-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.2 Quality of life (change from baseline to week 15). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.8 Serious adverse events (irrespective of attribution to treatment)." data-id="CD012838-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Pembrolizumab versus chemotherapy, outcome: 1.8 Serious adverse events (irrespective of attribution to treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 1 Overall survival." data-id="CD012838-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 1 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 2 Quality of life (change from baseline to week 15)." data-id="CD012838-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 2 Quality of life (change from baseline to week 15). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 3 Progression‐free survival." data-id="CD012838-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 3 Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 4 Response rate (partial and complete response)." data-id="CD012838-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 4 Response rate (partial and complete response). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 5 Treatment‐related mortality." data-id="CD012838-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 5 Treatment‐related mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 6 Discontinuation due to adverse event (any grade)." data-id="CD012838-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 6 Discontinuation due to adverse event (any grade). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 7 Serious adverse events (irrespective of attribution to treatment)." data-id="CD012838-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 7 Serious adverse events (irrespective of attribution to treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-001-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pembrolizumab versus chemotherapy, Outcome 8 Serious adverse events (irrespective of attribution to treatment)." data-id="CD012838-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Pembrolizumab versus chemotherapy, Outcome 8 Serious adverse events (irrespective of attribution to treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 1 Overall survival based on performance status." data-id="CD012838-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 1 Overall survival based on performance status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 2 Overall survival based on time since last chemotherapy." data-id="CD012838-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 2 Overall survival based on time since last chemotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 3 Overall survival based on degree of pretreatment." data-id="CD012838-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 3 Overall survival based on degree of pretreatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 4 Overall survival based on PD‐L1 tumour expression status." data-id="CD012838-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Pembrolizumab versus chemotherapy (predefined subgroup analyses), Outcome 4 Overall survival based on PD‐L1 tumour expression status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 1 Overall survival based on age." data-id="CD012838-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 1 Overall survival based on age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 2 Overall survival based on sex." data-id="CD012838-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 2 Overall survival based on sex. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 3 Overall survival based on smoking status." data-id="CD012838-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 3 Overall survival based on smoking status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 4 Overall survival based on histologic type." data-id="CD012838-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 4 Overall survival based on histologic type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 5 Overall survival based on PD‐L1 tumour expression status (10% cutoff)." data-id="CD012838-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 5 Overall survival based on PD‐L1 tumour expression status (10% cutoff). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 6 Overall survival based on location of primary tumour." data-id="CD012838-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 6 Overall survival based on location of primary tumour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 7 Overall survival based on location of metastases." data-id="CD012838-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 7 Overall survival based on location of metastases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 8 Overall survival based on liver metastases." data-id="CD012838-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 8 Overall survival based on liver metastases. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 9 Overall survival based on haemoglobin concentration." data-id="CD012838-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 9 Overall survival based on haemoglobin concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 10 Overall survival based on number of risk factors." data-id="CD012838-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 10 Overall survival based on number of risk factors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 11 Overall survival based on previous platinum therapy." data-id="CD012838-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 11 Overall survival based on previous platinum therapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012838-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/urn:x-wiley:14651858:media:CD012838:CD012838-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_t/tCD012838-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 12 Overall survival based on investigator's choice of chemotherapy." data-id="CD012838-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses), Outcome 12 Overall survival based on investigator's choice of chemotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/media/CDSR/CD012838/image_n/nCD012838-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012838-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Participants:</b> people with advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy </p> <p><b>Setting:</b> multicentre; 120 sites in 29 countries </p> <p><b>Intervention:</b> pembrolizumab </p> <p><b>Control:</b> chemotherapy (vinflunine or docetaxel or paclitaxel) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with chemotherapy</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with pembrolizumab</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to death from any cause</b> (here: overall mortality at 12‐month follow‐up) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>542<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.73<br/> (0.59 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>695 per 1000 <sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115 fewer per 1000<br/> (191 fewer to 38 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> (Change from baseline to week 15)<br/> Assessed with: EORTC QLQ‐C30<br/> Scale from 0 to 100 (a higher score represents better quality of life)<br/> Follow‐up: from baseline to week 15 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>519<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.05 (4.61 to 13.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life (change from baseline to week 15) was ‐8.3 score change <sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 9.05 score change higher<br/> (4.61 higher to 13.50 higher) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Response rate</b> (partial and complete response) </p> <p>Follow‐up: median 14.1 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>542<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.85<br/> (1.24 to 2.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 more per 1000<br/> (27 more to 202 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment‐related mortality</b><br/> Follow‐up: median 14.1 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/> (0.24 to 3.79) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 less per 1000<br/> (12 fewer to 44 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Discontinuation due to adverse event</b><br/> Follow‐up: median 14.1 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/> (0.39 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 fewer per 1000<br/> (67 fewer to 11 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Serious adverse events (irrespective of attribution to treatment)</b> </p> <p>Follow‐up: median 14.1 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>521<br/> (1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83</p> <p>(0.72 to 0.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>627 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 fewer per 1000<br/> (176 fewer to 19 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>RR 0.66, 95% CI 0.39 to 1.10<br/> <br/> <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>RR:</b> risk ratio; <b>RCT</b> : randomised controlled trial; <b>EORTC QLQ‐C30:</b>.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire‐C30 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Downgraded for imprecision due to wide confidence intervals. </p> <p><sup>2</sup> Downgraded for study limitations (performance and detection bias) </p> <p><sup>3</sup> Additonal concerns about selective reporting bias but not downgraded further. </p> <p><sup>4</sup> Downgraded for imprecision; 95% CI crosses minimal clinically important difference of 10. </p> <p><sup>a</sup> The baseline risk for death of any cause in the chemotherapy group was assumed to be 69.3% at 12 months as reported by Bellmunt 2017 (at 12 months, the estimated overall survival rate was 43.9% (95% CI 37.8 to 49.9) for participants treated with pembrolizumab and 30.7% (95% CI 25.9 to 36.7) for participants treated with chemotherapy). </p> <p>b Baseline risk for the chemotherapy group at 15 weeks as reported by Bellmunt 2017 ("From baseline to week 15, scores were stable for pembrolizumab (n = 266) (least squares [LS] mean +0.75 [95% CI –2.34 to +3.83]) but worsened for chemotherapy (n = 254) (LS mean –8.30 [95% CI –11.76 to –4.83]); the difference in LS means between arms was 9.05 (95% CI 4.61‐13.48; nominal 2‐sided P &lt; 0.001)"). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pembrolizumab compared to chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012838-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Trial period (year to year)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ethnic groups (%)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Bellmunt 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: pembrolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Median 14.1 months (for quality of life: from randomisation to week 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Participants with advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2014‐2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: paclitaxel or docetaxel or vinflunine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>C</b> : comparator; <b>I</b> : intervention; <b>‐</b>: not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012838-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant disposition</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention(s) and comparator(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N screened/eligible</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N ITT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N analysed for overall survival, progression‐frees survival, and response rate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N analysed for quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N analysed for treatment‐related mortality, discontinuation due to adverse events, and adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up<sup>a</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Bellmunt 2017</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I1: Pembrolizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Median 14.1 months (9.9‐22.1; for quality of life: from randomisation to week 15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: Paclitaxel or docetaxel or vinflunine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>255</p> </td> </tr> <tr> <td align="right" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Total:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>521</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Grand total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>270</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="3" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>272</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All interventions and comparators</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>542</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><sup>a</sup>Follow‐up under randomised conditions until end of trial or, if not available, duration of intervention. </p> <p><b>C</b> : comparator; <b>I</b> : intervention; <b>ITT</b>: intention‐to‐treat. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participant disposition</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/full#CD012838-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012838-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pembrolizumab versus chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life (change from baseline to week 15) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.05 [4.41, 13.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Response rate (partial and complete response) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.24, 2.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Treatment‐related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.24, 3.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Discontinuation due to adverse event (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.39, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serious adverse events (irrespective of attribution to treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Serious adverse events (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events (irrespective of attribution to treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Pruritus (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.00, 6.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Fatigue (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.28, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Diarrhoea (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.24, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Anaemia (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.37, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Constipation (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.11, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Peripheral sensory neuropathy (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Neutropenia (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.06, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.8 Alopecia (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.9 Hypothyroidism (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.10 Skin reaction (Grade 3, 4, or 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.05, 1.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pembrolizumab versus chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012838-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Pembrolizumab versus chemotherapy (predefined subgroup analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival based on performance status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ECOG 0‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ECOG 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.04, 4.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival based on time since last chemotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.58, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Less than 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.58, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Equal or greater than 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall survival based on degree of pretreatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Two prior treatments for metastatic disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 One prior treatment for metastatic disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.54, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.18, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall survival based on PD‐L1 tumour expression status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.51, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PD‐L1 positive (&gt;1% cut off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.43, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PD‐L1 negative (&lt;1% cut off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.66, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Pembrolizumab versus chemotherapy (predefined subgroup analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012838-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Overall survival based on age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.60, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.53, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ≥ 65 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.56, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival based on sex <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.56, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Female</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Overall survival based on smoking status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.41, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Current</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.15, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Former</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.52, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Never</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.72, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall survival based on histologic type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.54, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Transitional cell</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.62, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.37, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Overall survival based on PD‐L1 tumour expression status (10% cutoff) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.51, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 &lt; 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.61, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 ≥ 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.37, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall survival based on location of primary tumour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.54, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Upper tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.28, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Lower tract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Overall survival based on location of metastases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Lymph node only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.18, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Visceral disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.60, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall survival based on liver metastases <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Liver metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.61, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 No liver metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.50, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Overall survival based on haemoglobin concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 &lt; 10 g/dl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.46, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 ≥ 10 g/dl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.55, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Overall survival based on number of risk factors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 No risk factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.42, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 1 risk factor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.49, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 2 risk factors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 3 or 4 risk factors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.47, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Overall survival based on previous platinum therapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Cisplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.56, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Overall survival based on investigator's choice of chemotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Vinflunine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Pembrolizumab versus chemotherapy (post‐hoc included subgroup analyses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012838.pub2/references#CD012838-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012838.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012838-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012838-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012838-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012838-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012838-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012838-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012838\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012838\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012838\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012838\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012838\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uQyIsxpV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012838.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012838.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012838.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012838.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012838.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726508938"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012838.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726508942"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012838.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e955eba9cf3c9',t:'MTc0MDcyNjUwOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 